

Clinical efficacy outcomes are based on controlled clinical trials. Individual patient response may vary.

Glycaemic Control

- + In the SURPASS clinical trial programme, Tirzepatide demonstrated substantial reductions in HbA1c compared with active comparators.
- + Mean HbA1c reductions ranged from 1.8% to 2.4% from baseline, with a high proportion of patients achieving HbA1c <7.0%.
- + A greater proportion of patients achieved glycaemic targets without clinically significant hypoglycaemia.

Weight Management

- + Tirzepatide has demonstrated clinically meaningful weight reduction in adults with obesity when used in conjunction with diet and lifestyle modification.
- + Clinical Trial Data (SURMOUNT-1): At Week 72, mean percentage body-weight reductions were observed as follows:
 - 15.0% with 5 mg once weekly
 - 19.5% with 10 mg once weekly
 - 20.9% with 15 mg once weekly
 - Compared with 3.1% in the placebo group
- + At higher doses, more than 50% of patients achieved \geq 20% body-weight reduction.
- + Significant reductions in waist circumference were observed, consistent with loss of visceral adipose tissue.